Sixteen drugmakers have entered into or are negotiating confidential pricing deals with the Trump administration. Apart from the broad strokes laid out in public announcements, most details remain unknown.
President Donald Trump’s aim in making the deals is to correct the long-standing practice by pharmaceutical companies of charging Americans about three times more for prescription medications than those in other countries.
